RESOURCES

/

FIND A SPECIALIST

/

CONTACT

PODOMOUNT-pFSGS

Brief Description

The PODOMOUNT-pFSGS study is evaluating whether an investigational once daily oral medication called apecotrep reduces the amount of protein in the urine in adult patients with primary FSGS or genetic FSGS due to a mutation in the TRPC6 gene.

Trial Physician / Study Coordinator

Paige O'Connor

Estimated Enrollment

256

Estimated End Date

12/18/2029

Trial is for people with

Primary FSGS, as well as genetic FSGS due to TRPC6 gene mutation, diagnosed by biopsy, or genetic testing (genetic FSGS). People who ...

Study Goal

To learn more about the efficacy and safety of apecotrep and determine if it may help people with two rare kidney diseases—primary ...

What is involved for the patient?

You will receive either study drug (apecotrep) or placebo for up to 2 years. The randomization will be 1:1, meaning as many patients ...

About the drug or intervention

Apecotrep is a once daily non-immunosuppressant oral medication that is designed to protect podocytes, the cells which keep protein ...

Denver, CO

I'm Interested in this Trial

"*" indicates required fields

Your name*
This field is hidden when viewing the form
Your contact information will be sent to a team at
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
Have you ever had a kidney transplant?*
Are you currently on dialysis?*
Did you have a biopsy to confirm your diagnosis?*
Are you currently on the transplant wait-list?*
This field is hidden when viewing the form
This field is hidden when viewing the form
Interested in CT
Disclaimer

By clicking the submit button, your information and results will be sent to the study coordinator. Submitting the form does not guarantee enrollment but helps determine potential eligibility and connects you with the study team. Please consult your healthcare provider before pursuing participation in any trial.

Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

Clinical studies are any studies that involve people. There are two main types: observational and interventional. In an observational trial, researchers track health outcomes over time in groups of participants to look for patterns that help us better understand a disease. In an interventional trial, participants receive specific interventions, which can include new treatments or behavorial changes (e.g., diet changes). To learn more about clinical research, please visit the NephCure website.

See other frequently asked questions